论文信息 - The IL-28B Genotype Predicts Which Slow-Responding Hepatitis C-Infected Patients Will Benefit from Treatment Extension - 字舞流文

The IL-28B Genotype Predicts Which Slow-Responding Hepatitis C-Infected Patients Will Benefit from Treatment Extension

B. Pearlman | C. Ehleben

[1] William M. Lee,et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. , 2010, Gastroenterology.

[2] M. Strazzabosco. Foxa1 and Foxa2 regulate bile duct development in mice. , 2010, Journal of hepatology.

[3] C. Datz,et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. , 2010, Gastroenterology.

[4] D. Harnois. Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response , 2010 .

[5] Brian L. Pearlman,et al. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders , 2007, Hepatology.

[6] T. Berg,et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. , 2006, Gastroenterology.